AstraZeneca appoints Pam Cheng as Executive Vice President, Operations and IT

Tuesday, 16 June 2015

AstraZeneca today announced that Pam P. Cheng has joined the Company as Executive Vice President, Operations and IT. Pam will succeed David Smith, who is retiring after nearly ten years with AstraZeneca.

Pam will be responsible for manufacturing operations and supply chain, procurement and information technology globally. In the role she will oversee continued progress in driving efficiency and delivering excellence in these areas.

Pam joins AstraZeneca from Merck/MSD, where she gained extensive experience in pharmaceuticals manufacturing and supply chain management. She played a lead role in restructuring and upgrading the company’s manufacturing technology and engineering capabilities as Director of Global Planning and Capacity Management, and as Head of Global Supply Chain Management and Logistics led the transformation of the company’s supply chains across its global network. Most recently, Pam was Chief Operating Officer and then President of MSD China. Prior to joining Merck, Pam held Process Engineering roles at Union Carbide and GAF Chemicals.

Pascal Soriot, Chief Executive Officer, said: “I am delighted to welcome Pam to AstraZeneca at a very exciting time for our business. As our pipeline delivers, we will bring an increasing number of new medicines to patients across the globe over the coming years, including important biological therapies as our product mix shifts. Pam will be able to bring to bear her wealth of experience in manufacturing and supply chain management, as well as her experience in emerging markets, particularly China, a key priority for our company.”

“I also want to take the opportunity to thank David Smith for the invaluable contribution he has made to the leadership of AstraZeneca and to streamlining and expanding our global manufacturing footprint. The quality, reliability and cost effectiveness of our supply chain will be his legacy for many years to come.”

Pam will report to Pascal Soriot and will be a member of AstraZeneca’s Senior Executive Team. Pam holds bachelor’s and master’s degrees in Chemical Engineering from Stevens Institute of Technology in New Jersey and an MBA in Marketing from Pace University in New York.

Pam holds bachelor’s and master’s degrees in Chemical Engineering from Stevens Institute of Technology in New Jersey and an MBA in Marketing from Pace University in New York.

NOTES FOR EDITORS

To obtain a photograph of Pam Cheng please visit the AstraZeneca photo library or contact the media team (details below).

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

CONTACTS

Media Enquiries    
Esra Erkal-Paler (UK/Global) +44 20 7604 8030
Vanessa Rhodes (UK/Global) +44 20 7604 8037
Ayesha Bharmal (UK/Global) +44 20 7604 8034
Jacob Lund (Sweden) +46 8 553 260 20
Michele Meixell (US)
+1 302 885 6351

 

Investor Enquiries UK    
Thomas Kudsk Larsen +44 20 7604 8199 mob: +44 7818 524185

Eugenia Litz

(Respiratory, Inflammation and Autoimmunity)

+44 20 7604 8233 mob: +44 7884 735627

Nick Stone

(Cardiovascular and Metabolic Disease)

+44 17 6326 3994 mob: +44 7717 618834

Karl Hård

(Oncology)

+44 20 7604 8123 mob: +44 7789 654364

Craig Marks

(Infection, Neuroscience and Gastrointestinal Disease)

+44 20 7604 8591 mob: +44 7881 615764
Christer Gruvris +44 20 7604 8126 mob: +44 7827 836825

tags

  • Corporate and financial